The malaria vaccine candidate, RTS,S/AS01(E), showed promising protective efficacy in a trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the vaccine's safety and tolerability. The experimental design was a Phase 2b, two-centre, double-blind (observer- and participant-blind), randomised (1∶1 ratio) controlled trial. Three doses of study or control (rabies) vaccines were administered intramuscularly at 1 month intervals. Solicited adverse events (AEs) were collected for 7 days after each vaccination. There was surveillance and reporting for unsolicited adverse events for 30 days after each vaccination. Serious adverse events (SAEs) were recorded throughout the study period which lasted for 14 months after dose 1 i...
Background:A malaria vaccine could be an important addition to current control strategies. We report...
BACKGROUND: The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of ...
BACKGROUND: The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine dur...
The malaria vaccine candidate, RTS,S/AS01E, showed promising protective efficacy in a trial of Kenya...
The malaria vaccine candidate, RTS,S/AS01(E), showed promising protective efficacy in a trial of Ken...
The malaria vaccine candidate, RTS,S/AS01E, showed promising protective efficacy in a trial of Kenya...
BACKGROUND: RTS,S/AS01E is the lead candidate malaria vaccine. We recently showed efficacy against c...
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan...
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed R...
BACKGROUND: Plasmodium falciparum malaria is a pressing global health problem. A previous study of t...
BACKGROUND: A malaria vaccine could be an important addition to current control strategies. We repor...
The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up ha...
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed R...
BACKGROUND: An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malari...
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Sahara...
Background:A malaria vaccine could be an important addition to current control strategies. We report...
BACKGROUND: The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of ...
BACKGROUND: The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine dur...
The malaria vaccine candidate, RTS,S/AS01E, showed promising protective efficacy in a trial of Kenya...
The malaria vaccine candidate, RTS,S/AS01(E), showed promising protective efficacy in a trial of Ken...
The malaria vaccine candidate, RTS,S/AS01E, showed promising protective efficacy in a trial of Kenya...
BACKGROUND: RTS,S/AS01E is the lead candidate malaria vaccine. We recently showed efficacy against c...
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan...
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed R...
BACKGROUND: Plasmodium falciparum malaria is a pressing global health problem. A previous study of t...
BACKGROUND: A malaria vaccine could be an important addition to current control strategies. We repor...
The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up ha...
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed R...
BACKGROUND: An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malari...
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Sahara...
Background:A malaria vaccine could be an important addition to current control strategies. We report...
BACKGROUND: The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of ...
BACKGROUND: The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine dur...